A major immunological response during neuroinflammation is the activation of microglia, which subsequently release proinflammatory mediators such as prostaglandin E₂ (PGE₂). Besides its proinflammatory properties, cyclooxygenase-2 (COX-2)–derived PGE₂ has been shown to exhibit anti-inflammatory effects on innate immune responses. Here, we investigated the role of microsomal PGE₂ synthase-1 (mPGES-1), which is functionally coupled to COX-2, in immune responses using a model of lipopolysaccharide (LPS)–induced spinal neuroinflammation. Interestingly, we found that activation of E-prostanoid (EP)2 and EP4 receptors, but not EP1, EP3, PGI₂ receptor (IP), thromboxane A₂ receptor (TP), PGD₂ receptor (DP), and PGE₂ receptor (FP), efficiently blocked LPS-induced tumor necrosis factor α (TNFα) synthesis and COX-2 and mPGES-1 induction as well as prostaglandin synthesis in spinal cultures. In vivo, spinal EP2 receptors were up-regulated in microglia in response to intrathecally injected LPS. Accordingly, LPS priming reduced spinal synthesis of TNFα, interleukin 1β (IL-1β), and prostaglandins in response to a second intrathecal LPS injection. Importantly, this reduction was only seen in wild-type but not in mPGES-1–deficient mice. Furthermore, intrathecal application of EP2 and EP4 agonists as well as genetic deletion of EP2 significantly reduced spinal TNFα and IL-1β synthesis in mPGES-1–knock-out mice after LPS priming. These data suggest that initial inflammation prepares the spinal cord for a negative feedback regulation by mPGES-1–derived PGE₂ followed by EP2 activation, which limits the synthesis of inflammatory mediators during chronic inflammation. Thus, our data suggest a role of mPGES-1–derived PGE₂ in resolution of neuroinflammation.

Neurodegenerative disorders, including Alzheimer and Parkinson disease, multiple sclerosis, and spinal cord or peripheral nerve injury, are associated with neuroinflammation (1, 2). Its initiation, maintenance and resolution are regulated by various cell types, including resident microglia, astroglia, and oligodendrocytes as well as invading blood leukocytes. Lipopolysaccharide (LPS) has traditionally been used to simulate innate immune responses in the central nervous system (CNS) by activating toll-like receptor-4 of microglia (3). Upon activation, microglia release inflammatory mediators such as cytokines, chemokines, free radicals, nitric oxide, or prostaglandins (4). One of the earliest events during LPS-induced neuroinflammation is the synthesis and release of the proinflammatory cytokine TNFα by microglia, which reaches maximum concentrations 2–8 h after the initial inflammatory stimulus (5). In effector cells, TNFα induces the expression of multiple proteins that further enhance the inflammatory response, including cyclooxygenase-2 (COX-2) and the functionally coupled microsomal PGE₂ synthase-1 (mPGES-1) (6, 7). After 24 h, TNFα levels decrease to base-line levels whereas the activation of glia persists for several days (8). The mechanisms controlling the precise time course of the early innate immune responses depend on positive and negative feedback regulation loops and are not fully understood.

PGE₂, which acts via E-prostanoid (EP) receptors, fulfills contrasting roles as regulator of inflammatory responses (9). Its well-known proinflammatory properties are the reason for the clinical use of the anti-inflammatory acting COX inhibitors (10–12). In this regard, enhanced PGE₂ synthesis in the CNS can damage and/or sensitizes neurons, resulting in lesions or enhanced pain transmission (13–15). However, PGE₂ also has anti-inflammatory properties. It mediates bradykinin-induced neuroprotection and blocks LPS- and ATP-induced cytokine synthesis in cultured microglia or in neuron-glial cocultures (16, 17). The anti-inflammatory and neuroprotective effects of PGE₂ are suggested to be mediated via microglial EP2 and EP4 receptors. However, several studies have shown that EP2 or EP4 receptors are not expressed in microglia of naïve or injured animals in vivo (15). Accordingly, although COX-2 inhibitors elevate TNFα synthesis after a single intraperitoneal LPS injection, they do not have an effect on TNFα synthesis after a single intracerebroventricular LPS injection, indicating that PG-driven negative feedback con-

---

8 This work was supported by Deutsche Forschungsgemeinschaft Grant GE695 and the LOEWE Lipid Signaling Forschungszentrum Frankfurt.
9 The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1–4.
10 To whom correspondence should be addressed: Pharmazentrum Frankfurt, ZAFES, Institute of Clinical Pharmacology, Klinikum der Goethe-Universität Frankfurt, Theodor Stern Kai 7, 60590 Frankfurt, Germany. Tel.: 49-69-6301-67620; Fax: 49-69-6301-7617; E-mail: geisslinger@em.uni-frankfurt.de.

© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
Anti-inflammatory Role of mPGES-1

trols TNFα production in the periphery but not in the CNS (18).

Here, we used the well described model of chronic neuroinflammation by repetitive spinal LPS injection. In this model, where EP2 expression was up-regulated in microglia, we investigated the pro- and anti-inflammatory properties of PGE2 in vivo as well as the roles of COX-2 and mPGES-1 during termination of innate immune responses. We found that PGE2 attenuates LPS-induced TNFα synthesis in the spinal cord via EP2 receptors accompanied by a negative feedback inhibition on COX-2 expression. This effect was markedly reduced in mPGES-1-deficient mice which do not exhibit elevated PGE2 levels in response to LPS.

EXPERIMENTAL PROCEDURES

Animals—Crl:CFW(Sw) mPGES-1-deficient mice were kindly provided by Sanofi Aventis (Bridgewater, CT) and have been described previously (19). EP2 knock-out mice have been described previously (20). Transgenic mice were compared with strain-, age-, and sex-matched controls. For generation of spinal cultures, pregnant Sprague-Dawley rats were purchased from Janvier (Le Genest, St. Isle, France). In all experiments the ethics guidelines for investigations in conscious animals were obeyed, and the procedures were approved by the local Ethics Committee.

Reagents—EP receptor-specific ligands (EP1 agonist ONO-DI-004, EP2 agonist ONO-AE-1-259, EP3 agonist ONO-AE-248, and EP4 agonist ONO-AE-1-329) were kindly provided by Dr. Maruyama (ONO Pharmaceuticals, Sakurei, Japan). Cica-prost (dissolved in PBS) was a gift from Schering (Berlin, Germany). Generation and use of EP2- and EP4-specific antibodies have been described in detail previously (21). For immunohistochemistry antibodies against neuronal nuclei (Millipore), polyclonal IBA1 (Waco, Richmond, VA), glial fibrillary acidic protein (Sigma), and 7- amino actinomycin D (BD Pharmingen) were used.

Spinal Cord Cell Culture—Mixed spinal cord cell cultures were prepared as described previously with some changes (6, 19). Briefly, whole spinal cords were prepared from Sprague-Dawley rats at embryonic day 16–17. After dissociation, cells were plated onto poly-L-lysine (Sigma)-coated 3.5-cm dishes containing B-27 supplement (Invitrogen) and 0.01 g/ml mucoisobutylmethylxanthine and then treated for 5 min with 100 μM isobutylmethylxanthine and then treated for 15 min as indicated.

Western Blot Analysis—Spinal cord cells were directly homogenized in hot (95 °C) Laemmli buffer. Then, cell lysates containing 30 μg of protein were separated on 15% SDS-polyacrylamide gel. mPGES-1 was detected with a polyclonal antibody (1:1000) from AgriSera (Varaes, Sweden), COX-2, and EP2 with antibodies from Cayman (Ann Arbor, MI). An antibody against extracellular signal regulated kinase-2 (ERK-2) (Santa Cruz Biotechnology, Santa Cruz, CA) was used to detect for equal loading.

EP2 and EP4 receptors and COX-2 from spinal cord tissue were detected in membrane fractions. L4–6 spinal segments were homogenized in PBS with a potter and by sonification. Then the homogenate was centrifuged for 10 min at 10,000 × g and for 1 h at 170,000 × g. The pellet of the last centrifugation was resuspended in 50 μl of PBS containing 0.25 μM succrose and was used for Western blotting. Equal loading of membrane fraction was controlled with an antibody against β-actin (1:5000) from Santa Cruz Biotechnology.

RT-PCR—2 μg of total RNA from rat spinal cord was annealed with oligo(dT) primer and reverse-transcribed using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI). A VIC-TAMARA-labeled probe for 18S rRNA quantitation was from Applied Biosystems. Primers for amplification of EP2 were 5’-CCTGCGGCTGCTCAAC-TAGG-3’ and 5’-GTCTCCTCTGCAATCGAAGTCT-3’ and for EP4 5’-CTGAACAGCCGGTGAATCC-3’ and 5’-GCCGGCCAGCCGGTTGACC-3’. Real-time PCR was performed using the TaqMan system (Applied Biosystems) and the Absolute Blue quantitative PCR SYBR Green ROX mix (Thermo Fisher Scientific) according to the manufacturer’s instructions. Relative expression of EP2 and EP4 mRNA was determined using the comparative cycle threshold method, normalizing relative values to the average expression of 18S rRNA.

Cytokine Determination in Cell Culture Medium and Tissue Homogenate—TNFα and IL-1β were measured by enzyme immunoassay (EIA) kits from R&D Systems (Minneapolis, MN) according to the manufacturer’s protocol. Cell culture supernatant was used directly. Snap-frozen spinal cord (L4–6) tissue was thawed in 100 μl of phosphate-buffered saline (PBS) and homogenized with a potter. Then, 300 μl of PBS was added, and tissue was homogenized further by sonification. After centrifugation (10,000 × g), protein concentrations were determined in the supernatant, and 50 μg of protein/in 50 μl of PBS was used for the EIA.

cAMP Accumulation—cAMP levels were determined as described previously using the cAMP ELISA from R&D Systems (23). Cells were preincubated for 5 min with 100 μM isobutylmethylxanthine and then treated for 15 min as indicated.

Spinal (L4–5) tissues were prepared from mice that were perfused intracardially with 0.9% saline followed by 4% paraformaldehyde/PBS (pH 7.4). After a 24-h incubation in 30% sucrose/PBS, the tissue was cryostat-sectioned at 10 μm and stored at 4 °C until use. EP2 (1:2000) and EP4 receptors (1:1000) were detected with polyclonal rabbit antibodies (21), using the streptavidin-Cy3 detection system (Vector Laboratories, Burlingame, CA) according to the
Anti-inflammatory Role of mPGES-1

manufacturer's protocol. Here, signals were amplified by incubation with a biotinylated anti-streptavidin antibody followed by an additional incubation with streptavidin–Cy3 conjugate. For costaining we used DAPI (Applied Biochem) and CD11b:FITC (Serotec, Oxford, UK). For multiepitope ligand cartography spinal cord cells were grown on poly-L-lysine–coated coverslips as described above and fixed with 4% paraformaldehyde in PBS for 20 min at room temperature, permeabilized with 0.1% Triton X-100, and blocked with 5% goat serum in PBS. For the multiepitope ligand cartography analysis, antibodies were labeled with FITC as described (19, 24–26).

**Determination of Prostanoids by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)—**LC-MS/MS analysis of PGF₂α, PGE₂, PGD₂, TXB₂, and 6-keto-PGF₁α, from spinal tissue, and tissue culture supernatant was performed as described previously (27, 28).

Briefly, lumbar spinal cords were homogenized in 400 μl of PBS. 100 μl of homogenate containing 1 μg/μl protein was mixed with 50 μl of water, 20 μl of methanol, and 20 μl of internal standard solution (25 ng/ml [³H₄]PGE₂, [³H₄]PGD₂ and [³H₄]TXB₂, and 10 ng/ml [³H₄]PGF₂α, and [³H₄]6-keto-PGF₁α in methanol) and extracted twice with 800 μl of ethyl acetate. The combined organic phases were removed at a temperature of 45 °C under a gentle stream of nitrogen. The residues were reconstituted with 50 μl of acetonitrile/water/formic acid (20:80:0.0025, v/v, pH 4.0) and injected into the LC-MS/MS system. For detailed instrumentation and condition see online supplemental methods of Linke et al. (28).

For the detection of eicosanoids in cell culture supernatants, 500 μl of cell medium was mixed with 500 μl of 35 mM H₃PO₄, 20 μl of methanol, and 20 μl of internal standard solutions. Prostaglandins were extracted with solid phase extraction as described previously (28).

**Statistics—**For comparison between groups, data were subjected to two-tailed Student’s t test except where mentioned otherwise.

**RESULTS**

**Activation of EP2 and EP4 Receptors Inhibits LPS-induced TNFα Release in Primary Spinal Cord Cells—**We generated primary cultures from spinal cords of E17 embryonic rats in the absence of mitosis inhibitors to allow the survival of neurons and the growth of glia cells. Treatment of spinal cord cultures with 1 μg/ml LPS increased the TNFα concentration in the cell culture medium from undetectable levels to 507 ± 25 pg/ml (n = 6). EP2 and EP4 receptor agonists almost completely inhibited LPS-induced TNFα synthesis with IC₅₀ values of 3 nm and 1.7 nm, respectively (Fig. 1A). In contrast, agonists of other prostanoid receptors, such as EP1, EP3 (Fig. 1A), DP, FP, IP and TP (Fig. 1B) exhibited only marginal effects on TNFα synthesis at concentrations that were >1000-fold.
higher than their respective \( K_D \) values. EP2 and EP4 are known to activate cAMP synthesis through the stimulatory G protein \( G_s \) (29). Accordingly, agonists for EP2 and EP4 significantly increased the cAMP concentration in the spinal cord cells at a concentration of 0.1 \( \mu M \) (Fig. 1C), and the stable cAMP analog 8-bromo-cAMP was sufficient to mimic the effect of the EP2 and EP4 agonists on TNF-\( \alpha \) synthesis (Fig. 1D).

PGE\(_2\) Is A Negative Feedback Regulator during Spinal LPS-induced Immune Responses—TNF-\( \alpha \) induces spinal COX-2 and mPGES-1 expression as well as prostanoid synthesis in vivo and in vitro in primary spinal cord cultures (6, 7). Because activation of EP2 and EP4 receptors efficiently blocks LPS-induced TNF-\( \alpha \) synthesis in primary spinal cord cultures, we hypothesized that PGE\(_2\) may function as a negative feedback regulator to the enzymes necessary for its own production. Therefore, we incubated primary spinal cord cultures for various time periods with LPS and blocked endogenous prostanoid synthesis using either the unselective COX-1/2 inhibitor indomethacin or the selective COX-2 inhibitor rofecoxib. Both substances increased LPS-induced COX-2 expression significantly (Fig. 2, A and B). There was a tendency toward increased mPGES-1 expression after 5 h which reached significance only at late time points (Fig. 2, C and D). These findings suggest that COX-2-derived prostanoids inhibit LPS-induced expression of both genes. To identify prostanoids inhibiting LPS-induced COX-2 and mPGES-1 expression, we stimulated primary spinal cord cultures with LPS, inhibited endogenous prostanoid synthesis with rofecoxib, and added different prostanoids to activate their respective receptors. Due to the instability of prostacyclin, cicaprost was used as an IP receptor agonist (30). Interestingly, PGE\(_2\) was the only prostanoid that was able to block LPS-induced COX-2 and mPGES-1 expression significantly (Fig. 2, E and F). Notably, the inhibitory effect of PGE\(_2\) occurred at low nanomolar concentrations (Fig. 2, G and H).

To identify the EP receptor subtypes that mediated this negative feedback regulation by PGE\(_2\), we repeated the experiments using selective EP receptor agonists instead of PGE\(_2\) and found that EP2 and EP4 agonists inhibited LPS-induced COX-2 expression at low nanomolar concentrations. Similarly, EP2 agonists inhibited mPGES-1 expression (Fig. 3A) whereas both EP1 and EP3 agonists did not reduce COX-2 or mPGES-1 expression. Effects of the EP1 agonist at very high concentrations (10 \( \mu M \)) might be attributed to loss of receptor selectivity (\( K_I = 150 \text{ nm for EP1} \) (Fig. 3, A and B) (31)).

Next, we investigated whether or not EP2 and EP4 activation indeed causes a negative feedback inhibition which blocks the LPS-stimulated prostaglandin release. Therefore, we incubated primary spinal cord cultures with LPS and EP2 and EP4 agonists and determined prostanoid concentrations by LC-MS/MS. The EP2 agonist dose-dependently reduced the release of PGE\(_2\), PGD\(_2\), TXB\(_2\) (a stable metabolite of TXA\(_2\)), PGE\(_{2\alpha}\), and 6-keto-PGF\(_{1\alpha}\) (a stable metabolite of prostacyclin) (Fig. 3C). Similar results were obtained for inhibition of LPS-induced PGE\(_2\) synthesis using the EP4 agonist (Fig. 3C, inset). Taken together, these data suggest that COX-2-derived PGE\(_2\) limits its own synthesis via EP2/EP4 activation.

Influence of Altered Prostanoid Synthesis in mPGES-1-deficient Mice on Cytokine Synthesis during Acute LPS-induced Neuroinflammation—So far the in vitro data suggest that PGE\(_2\), but not other prostanoids, induces a negative feedback regulation via COX-2. Therefore, we investigated whether or not impaired endogenous PGE\(_2\) synthesis in mPGES-1-deficient mice correlates with increased innate immune responses and COX-2 activity also in vivo during LPS-induced neuroinflammation.

First, we determined the contribution of mPGES-1 to spinal prostanoid synthesis in response to a single intrathecal LPS injection. Prostanoid concentrations were measured in homogenates of spinal tissue from L4–5 segments in naïve animals as well as 3 h and 7 h after LPS injection by LC-MS/MS analysis. mPGES-1-knock-out mice exhibited significantly lower basal PGE\(_2\) levels and, in contrast to wild-type mice, no LPS-induced PGE\(_2\) synthesis was observed (Fig. 4A). In accordance with a previously described redirection of the prostanoid synthesis in mPGES-1-deficient mice (19, 32), spinal cords of mPGES-1-knock-out mice exhibited higher TXB\(_2\), PGE\(_{2\alpha}\), and 6-keto-PGF\(_{1\alpha}\) concentrations 3 and 7 h after stimulation with LPS. COX-2 protein levels in the spinal cord were increased 3–7 h after LPS injection (Fig. 4B). In mPGES-1-deficient mice, this up-regulation was not further increased compared with wild-type animals, indicating that initial immune responses that are induced by a single LPS injection are not affected by mPGES-1 deletion. Because mPGES-1 deficiency should not influence the quantitative metabolism of PGH\(_2\), we calculated the sum of prostanoids and used this value as a measure for COX-2 activity. In accordance to our findings for COX-2 expression, mPGES-1-deficient mice did not differ in their total prostanoid levels compared with wild-type mice 3–7 h after a single LPS injection (Fig. 4C).

Finally, we compared the time course of spinal TNF-\( \alpha \) synthesis after a single intrathecal LPS injection. Both wild-type and mPGES-1-knock-out mice showed substantially increased TNF-\( \alpha \) levels in spinal cord homogenates 3 h after LPS injection. 7 h after LPS injection, TNF-\( \alpha \) levels were still elevated but started to decline (Fig. 4D). This decline was significant in wild-type but not in mPGES-1-deficient mice, giving a first hint that termination of TNF-\( \alpha \) synthesis might depend on mPGES-1-derived PGE\(_2\) production.

LPS Priming Induces EP2 and EP4 Expression in Spinal Microglia and/or Invading Macrophages—Immunocytochemical analysis showed that EP2 receptors were predominantly expressed in amoeboid-shaped microglia (as shown by IBA staining), indicating that EP2 receptors are expressed on activated microglia. To a lesser extent, EP2 was also expressed in neurons (as shown by neuronal nuclei staining) (supplemental Figs. 1 and 2).

Because EP2 is not detected in ramified spinal microglia in vivo (15), we hypothesized that microglia activation and subsequent EP2 and EP4 receptor up-regulation after LPS pretreatment (priming) might be a precondition for the negative feedback regulation of PGE\(_2\) in the spinal cord. To test this hypothesis, we compared spinal EP2 and EP4 expression after a single or repeated intrathecal LPS injection. Wild-type and
mPGES-1-deficient mice, respectively, received by intrathecal application 27 h and 3 h before spinal cord preparation either twice a vehicle injection (ACSF) or a vehicle and a LPS injection, or two LPS injections. A significant up-regulation of EP2 mRNA, but not of EP4 mRNA, was seen using real-time RT-PCR in mice receiving two LPS injections (Fig. 5A). The up-regulation of EP2 was confirmed by Western blot analysis (Fig. 5B). Next, we analyzed EP2 and EP4 receptor expression in spinal sections of naïve and LPS-primed mice. CD11b costaining allowed the identification of microglia and/or macrophages, whose invasion into the spinal cord can also be induced by LPS (33). Upon LPS priming, amoeboid-shaped cells with strong CD11b staining appeared in the spinal cord. Costaining with antibodies against EP2 and EP4 revealed that
both receptors are expressed in the amoeboid CD11b-positive cells (Fig. 5, B and C). However, costaining of CD11b-positive cells with EP4 was only rarely seen (Fig. 5 C). Thus, the up-regulation of EP2 and its more prominent expression in CD11b-positive cells indicate that EP2 mediates the anti-inflammatory properties of PGE2 after repeated LPS stimulation.

FIGURE 3. EP2 and EP4 mediate the negative feedback regulation by PGE2. A and B, spinal cord cells were stimulated with 1 μg/ml LPS, 3 μM rofecoxib, and the respective EP receptor agonist for 21 h. Protein levels were determined by Western blotting. B, densitometric analysis of at least 2 independent experiments. Student’s t test: *, p ≤ 0.05. C, prostanoid concentrations in supernatants of spinal cord cultures that have been stimulated with 1 μg/ml LPS and the respective ONO-AE1–259-01 (EP2 agonist) concentrations. Inset, prostanoid concentrations in cultures treated with the indicated ONO-AE1–329 (EP4 agonist) concentrations. Data are shown as the average of at least 3 independent experiments. Student’s t test: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.005.

Reduction of Immune Responses after LPS Priming Is mPGES-1-dependent—Next, we investigated immune responses in wild-type and mPGES-1-deficient mice after increasing EP2 and EP4 expression in the spinal cord by LPS priming. Here, we compared TNFα, IL-1β, and prostanoid synthesis 3 h after LPS injection in mice of both genotypes which received LPS or vehicle 24 h earlier. We found that TNFα, IL-1β, and prostanoid concentrations (sum of PGE2, PGD2, TXB2, PGF1α, and 6-keto-PGF1α) were significantly lower after the second LPS administration in LPS-primed wild-type mice compared with mice that were not primed (Fig. 6, A–C). Most importantly, in accordance with our hypothesis that PGE2 inhibits LPS-induced innate immune responses, TNFα, IL-1β, prostanoid concentrations, and COX-2 expression were not significantly decreased in LPS-primed mPGES-1-deficient mice (Fig. 6, A–C, and supplemental Figs. 3 and 4).

To show that the altered response to LPS in mPGES-1-deficient mice is due to the lack of PGE2, we applied EP2 and EP4 agonists together with LPS to mPGES-1-deficient mice. Indeed, EP2 and EP4 agonists reduced spinal TNFα concentrations in mPGES-1-deficient mice in primed and unprimed animals (Fig. 6D). However, the reduction of TNFα concentrations was significantly more pronounced in LPS-primed mPGES-1 knock-out mice. Interestingly, in EP2 knock-out mice, no significant decrease in the synthesis of prostanooids, IL-1β, or TNFα was observed (Fig. 6, E–G), suggesting that in vivo EP2 is the receptor mediating the anti-inflammatory response of PGE2 in our model of neuroinflammation. In summary, our data suggest that LPS priming renders the spinal cord competent for negative feedback regulation via mPGES-1-derived PGE2 by up-regulating EP2 receptors.
DISCUSSION

COX-2-derived PGE$_2$ is a known regulator of neuroinflammatory processes in several neurological disorders such as multiple sclerosis, traumatic brain injury, Alzheimer and Parkinson disease as well as spinal cord injury (15, 34). In experimental models, conditions of neuroinflammation, including increased PGE$_2$ synthesis, can be induced by LPS injection into the CNS (3). Here, we describe that PGE$_2$ limits cytokine and prostaglandin synthesis mainly through EP2 activation in a model of LPS-induced neuroinflammation and that mPGES-1 is a critical enzyme in this negative feedback regulation (Fig. 7).

Previously, PGE$_2$ was shown to block innate immune responses from microglia in vitro via EP2 and EP4 (16, 17, 35). Here, we found that EP2- and EP4-expressing spinal microglia had an amoeboid morphology that is characteristic for activated microglia. In vivo, EP2 has a predominantly neuronal localization in the murine spinal cord, whereas ramified spinal microglia does not express EP2 (14, 15, 36, 37). However, EP2 and EP4 expression in microglia and astrocytes, respectively, was induced in the superoxide dismutase model for lateral sclerosis or in the ischemic brain, suggesting that the expression of microglial EP2 is limited to activated microglia (15, 38, 39).

Because only activated microglia expressed EP2 and EP4, we activated microglia by intrathecal application of LPS 24 h before administering a second LPS injection. In this model increased CD11b immunoreactivity was detected in amoeboid-shaped cells in the spinal cord, which is indicative for an activation of resident microglia or immigration of macrophages into the spinal cord. Most importantly, after LPS priming, the CD11b-positive cells expressed EP2 and EP4. However, only EP2 is up-regulated after the first LPS stimulation, and genetic deletion of EP2 was sufficient to prevent the anti-inflammatory effects of PGE$_2$ suggesting that in our in vivo model mostly EP2 mediates the anti-inflammatory effects.
of PGE_2. The appearance of EP2 suggests that an initial inflammation (priming) in the spinal cord is necessary to enable the inhibitory effect of PGE_2 on cytokine synthesis and to initiate a negative feedback loop. Accordingly, LPS-primed mice produced less TNF\alpha, IL-1\beta, and prostanoids compared with mice that were not primed. These data are supported by the findings that the synthesis of proinflammatory cytokines as well as antigen-presenting cell functions were diminished after systemic pretreatment with LPS (8).

Surprisingly, in mPGES-1-deficient mice, the attenuation of immune responses after LPS priming was completely absent, suggesting that PGE_2 is a component of priming-induced resolution of inflammation. Furthermore, we found that proximate to PGE_2 signaling in microglia COX-2 expression was also blocked. A selective shift of COX-2-mediated prostanoid synthesis by mPGES-1 to PGE_2 might therefore be a key step in the termination of cytokine and prostaglandin production. Previously it was postulated that COX-2-activity in the CNS has no effect on LPS-induced cytokine synthesis (18). However, in that study the TNF\alpha synthesis was determined in response to a single LPS application. In accordance to this finding, we also observed no differences between wild-type and mPGES-1-deficient mice after a single LPS application. The negative feedback by PGE_2 was only observed when LPS was injected twice. This dependence of microglial activation suggests a physiological function of the negative feedback loop mainly during chronic neuroinflammation. Hence, a single LPS injection was not sufficient to increase EP2 or EP4 expression within the next 3 h in the spinal cord. Consequently, the time course of spinal TNF\alpha concentrations also showed no significant differences between wild-type and mPGES-1-deficient mice after a single intrathecal LPS injection. The period of TNF\alpha synthesis after a single LPS injection seems to be too short to induce microglial EP2 expression and, therefore, to permit the negative feedback inhibition of PGE_2.

FIGURE 5. LPS priming induces EP2 and EP4 expression in spinal microglia and/or invading macrophages. A, mRNA levels of EP2 and EP4 were determined by real-time RT-PCR in L4–S spinal segments of wild-type mice receiving 27-h and 3-h prior preparation of either ACSF twice or ACSF and LPS twice or LPS twice. Protein homogenates of six animals were pooled. B, same as A except that EP2 expression is shown by Western blot analysis. In the lower panel the densitometric analysis of expression in 3–4 mice is shown. Student’s t-test: **, p < 0.01. C and D, Immunohistochemical analysis of spinal cord tissue sections from naïve and LPS-primed mice. EP2 (B) and EP4 (C) expression shown in red were costained with CD11b for microglia and/or macrophages (green). Shown are representative regions from spinal cord white matter. Scale bars, 20 μm.
Several cAMP-elevating agents can inhibit or at least reduce TNFα synthesis (40, 41). Because EP2, EP4, IP, DP, and certain splice variants of EP3 increase cAMP generation (42), all of these receptors are theoretically able to attenuate TNFα-mediated immune responses by PGE2. However, we found that in primary spinal cord cultures only activation of EP2 and EP4 was able to block TNFα synthesis, whereas the activation of other prostanoid receptors had no effect on the cytokine synthesis. These data were supported by the fact that mPGES-1-deficient mice lacked the negative feedback regulation. We and others showed that mPGES-1 deficiency causes a redirection of eicosanoid synthesis from PGE2 to other prostanoids causing, for example, a functional compensation for the loss of PGE2 in zymosan-induced hyperalgesia (19, 32). Due to the availability of the COX-2 product PGH2, the tissue-specific expression of other terminal prostaglandin synthases decides the fate of PGH2 and directs the specific prostaglandin production. However, in this study no functional compensation by other prostanoids was observed, showing that also in vivo only PGE2 was able to induce negative feedback regulation and to inhibit cytokine synthesis or COX-2 and mPGES-1 expression. The observed PGE2-specific anti-inflammatory effect underlines the importance of the selective isomerization of COX-2-derived PGH2 by mPGES-1 in the regulation of neuroinflammatory processes.

Because it is known that COX-2 and mPGES-1 expression in microglia, neurons, and endothelial cells is induced by proinflammatory cytokines, such as TNFα and IL-1β (6, 43–45), it was not surprising that activation of EP2 and EP4 receptors also prevented LPS-induced COX-2- and mPGES-1

**FIGURE 6.** LPS priming reduces immune responses in a mPGES-1- and EP2/4-dependent manner. A, determination of TNFα concentrations by EIA from tissue homogenates of L4–5 spinal segments from mPGES-knock-out or wild-type mice receiving 27-h and 3-h prior preparation of either ACSF twice or ACSF and LPS twice or LPS twice. n.s., not significant. B, same as in A except IL-1β levels were determined. C, same as in A and B, except that prostanoids were determined. Data are shown as the sum of all prostanoids (PGE2, PGD2, PGF2α, 6-keto-PGF1α, and TXB2) detected in the tissue samples. D, 100 μM EP2 and EP4 agonists were injected intrathecally together with LPS in naive or LPS-primed mPGES-knock-out mice. After 2 h, L4–5 spinal segments were dissected, and TNFα levels were determined by EIA. Data are shown in percent inhibition compared with mPGES-1-knock-out mice which received no agonists. All data are shown as the mean ± S.E. (error bars) from 6–8 animals per genotype and stimulation condition. Student’s t test: *, p < 0.05. E–G, EP2-knock-out mice were injected intrathecally together with LPS in naive or LPS-primed mPGES-knock-out mice. After 2 h L4–5 spinal segments were dissected, and prostanoids (E), IL-1β (F), or TNFα (G) levels were determined by EIA. All data are shown as the mean ± S.E. from 8 animals per condition.
expression as well as prostanoid synthesis. In accordance with the literature, our results suggest a dual contrasting role of PGE2 during neuroinflammation in the spinal cord. Early in inflammation, cytokines induce COX-2 expression in different cell types. This leads to an increased synthesis of various prostanoids causing deleterious effects on neurons (13, 14, 37, 46). Subsequently, expression of mPGES-1 shifts COX-2-derived prostanoid synthesis and PGE2 reaches maximum levels. However, during sustained inflammation, mimicked by a second LPS injection, microglial cells start to express EP2, which enables PGE2 to have an additional anti-inflammatory effect. PGE2 now blocks further cytokine synthesis, which is necessary for the induction of COX-2 expression. Taken together, our data may therefore identify mPGES-1 as an essential step for the control of innate immune responses during chronic inflammation in the spinal cord. They indicate that the same pathway that initially promotes inflammation later on contributes to its resolution, a process that physiologically is of
high importance and may also have clinical consequences in pharmacotherapy with nonsteroidal anti-inflammatory drugs or selective mPGES-1 inhibitors, which are currently under development.

Previous studies on LPS preconditioning in the CNS focused mainly on its effect on hypoxic ischemia-induced neurodegeneration. It was shown that systemic LPS- or ischemia-induced preconditioning causes neuroprotection as a long term outcome through mechanisms involving several different pathways including COX-2, nitric-oxide synthase, and reactive oxygen species (47–49). Interestingly, also in the hypoxic slice culture model by Kim et al. (47) COX-2 activity was crucial for preconditioning-induced neuroprotection.

Our study adds additional insights in the preconditioning effects by specifying the underlying downstream (of COX-2) mechanism to mPGES-1 activity and EP2 activation. It further demonstrates the existence of an anti-inflammatory preconditioning effect in the adult spinal cord after local LPS application. This indicates that during chronic neuroinflammation a direct pathogen action on resident microglia or invading macrophages is sufficient to dampen the ongoing innate immune responses. Whether this has a neuroprotective outcome needs to be investigated in further studies.

Despite the fact that we found anti-inflammatory properties, PGE2 has often been shown to promote neuronal damage during injury (13, 50). A reason for these differences may be that microglia-derived TNFα can be neuroprotective as described for ischemia (51). To date, it has not been established whether proinflammatory cytokines contribute to or limit neuronal injuries during neurological disorders, including ischemia, traumatic brain injury, multiple sclerosis, and Alzheimer or Parkinson disease (52). Therefore, it is difficult to predict how inhibition of mPGES-1 and COX-2, which may increase cytokine synthesis during chronic neuroinflammation, will affect the clinical outcome of these neurological disorders.

Acknowledgments—We thank Wiebke Becker and Marina Henke for excellent technical assistance.

REFERENCES

1. Griffin, R. S., Costigan, M., Brenner, G. J., Ma, C. H., Scholz, J., Moss, A., Allchorne, A. J., Stahl, G. L., and Woolf, C. J. (2007) J. Neurosci. 27, 8699–8708
2. Skaper, S. D. (2007) Ann. N.Y. Acad. Sci. 1122, 23–34
3. Lehnardt, S., Massillon, L., Follett, D., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., and Vartanian, T. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 8514–8519
4. Herber, D. L., Maloney, J. L., Roth, L. M., Freeman, M. J., Morgan, D., and Gordon, M. N. (2006) Glia 53, 382–391
5. Shen, A., Zhou, D., Shen, Q., Liu, H. O., Sun, L., Liu, Y., Chen, J., Yang, J., Ji, Y., and Cheng, C. (2009) Neurochem. Res. 34, 333–341
6. Brenneis, C., Maier, T. J., Schmidt, R., Hofacker, A., Zulauf, L., Jakobsen, P. J., Scholich, K., and Geisslinger, G. (2006) FASEB J. 20, 1352–1360
7. Narita, M., Shimamura, M., Imai, S., Kubota, C., Yajima, Y., Takagi, T., Shiozaki, M., Inoue, T., Suzuki, M., and Suzuki, T. (2008) Neuroscience 152, 477–486
8. Buenafe, A. C., and Bourdette, D. N. (2007) J. Neuroimmunol. 182, 32–40
9. Hata, A. N., and Breyer, R. M. (2004) Pharmacol. Ther. 103, 147–166
10. Fitzgerald, G. A., and Patrono, C. (2001) N. Engl. J. Med. 345, 433–442
11. Fitzgerald, G. A. (2004) N. Engl. J. Med. 351, 1709–1711
12. Scholich, K., and Geisslinger, G. (2006) Trends Pharmacol. Sci. 27, 399–401
13. Montine, T. J., Milatovic, D., Gupta, R. C., Valyi-Nagy, T., Morrow, J. D., and Breyer, R. M. (2002) J. Neurochem. 83, 463–470
14. Reindold, H., Ahmadi, S., Depner, U. B., Layh, B., Heindl, C., Hamza, M., Pahl, A., Brune, K., Narumiya, S., Müller, U., and Zeilhofer, H. U. (2005) J. Clin. Invest. 115, 673–679
15. Zhao, P., Wxman, S. G., and Hains, B. C. (2007) J. Neurosci. 27, 2357–2368
16. Caggiato, A. O., and Kraig, R. P. (1999) J. Neurochem. 72, 565–575
17. Noda, M., Hara, S., Uchida, M., Uchida, Y., Tanaka, T., Suda, T., and Narumiya, S. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 9835–9840
18. Li, Q., Hu, L., and Yamauchi, T. (2004) J. Biol. Chem. 279, 53342–53353
19. Montine, T. J., Milatovic, D., Gupta, R. C., Valyi-Nagy, T., Morrow, J. D., and Breyer, R. M. (2002) J. Neurochem. 83, 463–470
Anti-inflammatory Role of mPGES-1

Cell. Immunol. 120, 291–300
41. Seldon, P. M., Barnes, P. J., Mejia, K., and Giembycz, M. A. (1995) Mol. Pharmacol. 48, 747–757
42. Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., Hirata, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 2712–2718
43. Engblom, D., Saha, S., Engström, L., Westman, M., Audoly, L. P., Jakobsson, P. J., and Blomqvist, A. (2003) Nat. Neurosci. 6, 1137–1138
44. Ikeda-Matsuo, Y., Ikegaya, Y., Matsuki, N., Uematsu, S., Akira, S., and Sasaki, Y. (2005) J. Neurochem. 94, 1546–1558
45. Samad, T. A., Moore, K. A., Sapirstein, A., Billet, S., Allchorne, A., Poole, S., Bonventre, J. V., and Woolf, C. J. (2001) Nature 410, 471–475
46. Zeilhofer, H. U. (2005) Cell. Mol. Life Sci. 62, 2027–2035
47. Kim, E., Raval, A. P., Defazio, R. A., and Perez-Pinzon, M. A. (2007) Neuroscience 145, 931–941
48. Lin, H. Y., Huang, C. C., and Chang, K. F. (2009) Pediatr. Res. 66, 254–259
49. Lin, H. Y., Wu, C. L., and Huang, C. C. (2010) Stroke 41, 1543–1551
50. Strauss, K. I. (2008) Brain Behav. Immun. 22, 285–298
51. Lamberts, K. L., Clausen, B. H., Babcock, A. A., Gregersen, R., Fenger, C., Nielsen, H. H., Haugaard, L. S., Wirenfeldt, M., Nielsen, M., Dagnaes-Hansen, F., Bluethmann, H., Faergeman, N. J., Meldgaard, M., Deierborg, T., and Finsen, B. (2009) J. Neurosci. 29, 1319–1330
52. McCoy, M. K., and Tansey, M. G. (2008) J. Neuroinflammation 5, 45